Worth reading
39Recurring
Scored from 4 of 5 sectionsDirection
Improvement
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Conditional
How definitive the wording is.Agreements reached under this partnership
Business Alliance4884Kringle Pharma,Inc.
Alliance partnerClaris Biotherapeutics
Details of the alliance
- 1
Sharing safety information on recombinant human dHGF protein
- 2
Collaborative framework for optimizing the manufacturing process
These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.
About the partner
Business DescriptionAdvancing the development of recombinant human dHGF protein as an ophthalmic drug. Conducting clinical trials in the United States for limbal stem cell deficiency (LSCD) and corneal scarring
| Item | Details |
|---|---|
| Name of alliance partner | Claris Biotherapeutics |
| Alliance partner's business activities | Advancing the development of recombinant human dHGF protein as an ophthalmic drug. Conducting clinical trials in the United States for limbal stem cell deficiency (LSCD) and corneal scarring |
| Type of alliance | Business Alliance |
| Details of the alliance | Sharing safety information on recombinant human dHGF protein, Collaborative framework for optimizing the manufacturing process |
Items this document does not state (19)
Alliance partner's locationAlliance partner's capitalAlliance partner's net salesAlliance partner's operating incomeNumber of shares acquiredAcquisition priceShareholding ratioOverview of the joint ventureOwnership ratioDispatch of directors and officersContract PeriodNumerical targets under the allianceShareholding PolicyDate of board resolutionContract DateAlliance start dateShare Acquisition Date and Payment DateImpact on Business PerformanceChange in major shareholders
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Claris presented clinical proof-of-concept data for CSB-001 in LSCD in an oral presentation at the American Academy of Ophthalmology’s 2026 annual meeting.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.